Table 2.
Active regimens for extra-pulmonary poorly differentiated neuroendocrine carcinomas.
| Author | Year | Regimen | N. of pts | Histology | ORR | mPFS (months) | mOS (months) |
|---|---|---|---|---|---|---|---|
| Moertel et al. | 1991 | EP | 18 | PDNEC | 67% | 11 | 19 |
| Mitry et al. | 1999 | EP | 41 | PDNEC | 41.5% | 8.9 | 15 |
| Fjallskog et al. | 2001 | EP | 36 | Mixed - NET | 55% | NI | 19 |
| Sorbye et al. | 2012 | EP | 129 | PDNEC | 31% | 4.0 | 1.0 |
| Hou et al. | 2003 | IP | 14 | PDNEC | 43% | NI | NR |
| Mani et al. | 2008 | IP | 20 | PDNEC | 58% | 4 | NI |
| Okita et al. | 2011 | IP | 37 | Gastric NET | 75% | 7.1 | 22.6 |
| Nakano et al. | 2012 | IP | 50 | PDNEC | 50% | 4.8 | NR |
| Yamagugchi et al. | 2012 | IP/EP | 206 | PDNEC | 50/27% | 5.2/4 | 13/7.3 |
| Hainsworth et al. | 2006 | PCE | 78 | PDNEC | 53% | 7.5 | 14.5 |
| Bajetta et al. | 2007 | CapOx | 13 | PDNEC | 23% | 4.0 | 5.0 |
| Ferrarotto et al. | 2011 | CapOx | 24 | NET/PDNEC | 29% | 9.8 | NR |
EP, etoposide and platin; IP, irinotecan and platin; PCE, ,paclitaxel, carboplatin, etoposide; CapOx, capecitabine and oxaliplatin; PDNEC, poorly differentiated neuroendocrine carcinomas; NET, neuroendocrine tumors; ORR, overal response rate; mPFS, median progression free survival; mOS, median overall survival; NI, not informed; NR, not reached.